Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06830863 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
A Phase 1 study of EGFR Inhibitor-associated Rash, sponsored by Azitra.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 6
- Study locations
NCT06830863 is a Phase 1 study of EGFR Inhibitor-associated Rash that is actively recruiting participants, run by Azitra. The registered enrollment target is 32 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT06830863, a Phase 1 study of EGFR Inhibitor-associated Rash, is actively recruiting participants, sponsored by Azitra.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will: * Apply ATR04-484 or vehicle daily for 28 days * Visit the clinic periodically for evaluation and sample collection
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG ATR04-484
Study Locations (6)
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
Connecticut
- Yale University School of Medicine - New Haven
New York
- NYU Langone - New York
Ohio
- The Ohio State University - Gahanna
Texas
- MD Anderson - Houston
Virginia
- Inova Schar Cancer - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06830863
The ClinicalTrials.gov registry entry for NCT06830863 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azitra, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with EGFR Inhibitor-associated Rash appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT06830863 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arkansas, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT06830863 about?
NCT06830863 is a clinical study titled "A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity". The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess e...
What is the current status of trial NCT06830863?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-08-25. Estimated completion is 2027-02-15.
What conditions does trial NCT06830863 study?
This clinical trial studies the following conditions: EGFR Inhibitor-associated Rash.
What interventions are being tested in trial NCT06830863?
The interventions under investigation include: Vehicle (DRUG), ATR04-484 (DRUG).
Who is sponsoring clinical trial NCT06830863?
This trial is sponsored by Azitra, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06830863 being conducted?
This trial has 6 study locations across Arkansas, Connecticut, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for EGFR Inhibitor-associated Rash
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.